Mara D. Chambers, MD
REQUEST AN APPOINTMENT
Are you a physician?
Refer a Patient
Specialties
Conditions
About
Faculty Rank
- Associate Professor of Medicine
Training & Education
Degree
University of Louisville School of Medicine
Residency
University of Louisville School of Medicine
Fellowship
Medical Oncology and Hematology, University of Kentucky
Certifications and Special Training
American Board of Internal Medicine, Medical Oncology
Research
Publications
- A Narrative Review of the Confluence of Breast Cancer and Low-wage Employment and Its Impact on Receipt of Guideline-recommended Treatment.Vanderpool RC, Swanberg JE, Chambers MD. Glob Adv Health Med. 2013 Sep;2(5):75-85.
- Iron deficiency anemia.Killip S, Bennett JM, Chambers MD. Am Fam Physician. 2007 Mar 1;75(5):671-8.
- Plasma TNF-α and soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study.Hayslip J, Dressler EV, Weiss H, Taylor TJ, Chambers M, Noel T, Miriyala S, Keeney JT, Ren X, Sultana R, Vore M, Butterfield DA, St. Clair D, Moscow JA. PLoS One 2015 Apr 24; 10 (4): e0124988.
- Impact of estrogen receptor (ER) and human epidermal growth factor receptor- 2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, Awasthi M, Massarweh S. Breast Cancer Res Treat. 2014 Nov; 148 (2): 437-44 Abstracts/Presentations.
- Everolimus benefit in estrogen receptor (ER)-positive breast cancer is not linked to genomic alterations of the PI3K/AKT/mTOR pathway.Suleiman Massarweh, Edward Romond, Juliann Chmielecki, James Sun, Vera Kadamyan-Melkumyan, Mara Chambers, Rachel Stewart, Emily Van Meter Dressler, Murtaza Mehdi, Craig Horbinski, and Esther P Black. Stanford University and Cancer Institute, Stanford, CA 94304, University of Kentucky and Markey Cancer Center, Lexington, KY 40536, and Foundation Medicine, Cambridge, MA, United States
- Mutations in distinct components of the PI3K/AKT/mTOR pathway may define endocrine sensitivity in estrogen receptor (ER)-positive breast cancer.Esther P Black, Edward Romond, Juliann Chmielecki, James Sun, Rachel Stewart, Emily Van Meter Dressler, Vera Kadamyan-Melkumyan, Mara Chambers, Craig Horbinski, Murtaza Mehdi, and Suleiman Massarweh. Stanford University and Cancer Institute,
Stanford, CA 94304, University of Kentucky and Markey Cancer Center, Lexington, KY 40536, and Foundation Medicine, Cambridge, MA, United States. - A phase II study of combined fulvestrant and RAD001 (everolimus) in metastatic estrogen receptor (ER) positive breast cancer after aromatase inhibitor (A1) failure.Croley J, Black EP, Romond E, Chambers M, Waynick S, Slone S, Waynick C, Stevens M, Weiss H, and Massarweh S. Poster Presentation, San Antonio Breast Cancer Symposium, 2012.
- A phase II trial of fulvestrant and RAD001 (Everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure; A study in progress.Badin F, Romond E, Chambers M, Shelton B, Birk S, Kadamyan V, Weiss H, and Massarweh S. Cancer Res 2010; 70(24 suppl): Abstract nr P4-02-05.